Eli Lilly (NYSE:LLY), like many of its peers in the pharma industry, continues to battle the effects of the patent cliff. Two of its three top-selling products will lose exclusivity this year, but there is one jewel in its crown that investors don't need to worry about. In this video, health care analyst Max Macaluso dives into this drug's clinical use and growth.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.